Outpatient imaging diagnostics provider Lumexa Imaging Holdings (LMRI.US) filed for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC) on Monday, seeking to raise up to $200 million. As a nationwide outpatient diagnostic imaging services provider, Lumexa Imaging operates 184 diagnostic centers across 13 states through wholly-owned operations and joint ventures with healthcare systems. The company offers a range of advanced and routine imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), X-rays, ultrasound, and mammography.

Founded in 2018 through a partnership between Charlotte Radiology and investment firm Welsh, Carson, Anderson & Stowe, Lumexa initially had only 20 centers. Since then, it has expanded through 20 acquisitions and the opening of 41 new locations. The company has built a diversified referral network, collaborating with approximately 100,000 physicians across more than 29,000 healthcare facilities.

Headquartered in Raleigh, North Carolina, Lumexa reported $1 billion in revenue for the 12 months ending September 30, 2025. The company plans to list on the Nasdaq under the ticker symbol "LMRI" and submitted a confidential draft registration statement on June 12, 2025.

Barclays, J.P. Morgan, Jefferies, Deutsche Bank, Wells Fargo Securities, Leerink Partners, William Blair, Capital One Securities, Fifth Third Securities, Raymond James, and PNC Capital Markets are serving as joint bookrunners for the IPO. Pricing terms have not yet been disclosed.